Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Target Oncol
.
2020 Dec;15(6):807.
doi: 10.1007/s11523-020-00772-4.
Authors
Dietger Niederwieser
1
2
3
,
Caroline Hamm
4
,
Patrick Cobb
5
,
Mindy Mo
6
,
Cecily Forsyth
7
,
Alessandra Tucci
8
,
Vladimir Hanes
6
,
Vincent Delwail
9
,
Roman Hajek
10
,
David Chien
6
Affiliations
1
Division of Hematology and Oncology, University of Leipzig, Liebigstr. 19, 04106, Leipzig, Germany.
[email protected]
.
2
Lithuanian University of Health Sciences, Kaunas, Lithuania.
[email protected]
.
3
School of Medicine, Aichi Medical University, Nagakute, Aichi/Nagoya, Japan.
[email protected]
.
4
Schulich School of Medicine, Western University, Windsor, ON, Canada.
5
St. Vincent Frontier Cancer Center, Billings, MT, USA.
6
Amgen Inc., Thousand Oaks, CA, USA.
7
Gosford Hospital, Gosford, NSW, Australia.
8
Hematology Department, ASST-Spedali Civili-Brescia, Brescia, Italy.
9
Oncology-Hematology and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
10
Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
PMID:
33180232
PMCID:
PMC7701060
DOI:
10.1007/s11523-020-00772-4
Abstract
Page 608, 4 Discussion, right column, second paragraph.
Publication types
Published Erratum